AbbVie Exceeds Revised 2025 EPS Guidance, Reports Strong Q4 & Full-Year Results, and Issues Robust 2026 Outlook
Summary
AbbVie reported Q4 and full-year 2025 financial results, exceeding its previously revised 2025 adjusted EPS guidance and providing a strong 2026 adjusted EPS outlook.
Key Events
-
Exceeded Revised 2025 Adjusted EPS Guidance
AbbVie reported full-year 2025 adjusted diluted EPS of $10.00, surpassing the revised guidance of $9.90-$9.94 issued on January 7, 2026.
-
Strong Full-Year 2025 Revenue Growth
Full-year net revenues reached $61.160 billion, an increase of 8.6% on a reported basis, driven by key growth products.
-
Robust 2026 Adjusted EPS Guidance Issued
The company provided new full-year 2026 adjusted diluted EPS guidance in the range of $14.37 to $14.57.
-
Key Portfolio Performance Highlights
Immunology portfolio revenues grew 14.0% (reported), with Skyrizi up 49.9% and Rinvoq up 39.1%. Neuroscience portfolio revenues increased 19.6% (reported), while Humira revenues declined 49.5% (reported) post-exclusivity.
Analysis
AbbVie Inc. reported strong financial results for the fourth quarter and full year 2025, with full-year adjusted diluted EPS of $10.00, which surpassed the previously revised guidance of $9.90-$9.94 issued on January 7, 2026. The company demonstrated robust revenue growth, particularly in its immunology and neuroscience portfolios, offsetting the expected decline in Humira sales post-exclusivity. The new full-year 2026 adjusted diluted EPS guidance of $14.37 to $14.57 provides a positive outlook for investors, signaling continued growth and successful diversification beyond Humira.
At the time of this filing, ABBV was trading at $229.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $398.8B. The 52-week trading range was $164.39 to $244.81. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.